Cargando…

in vitro effects of ICRF 159.

Detalles Bibliográficos
Autores principales:	Hellmann, K., Hallowes, R. C.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1973
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009031/ https://www.ncbi.nlm.nih.gov/pubmed/4737507

Ejemplares similares

Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159.
por: Hellmann, K., et al.
Publicado: (1974)

The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
por: Albanese, R., et al.
Publicado: (1985)

Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
por: Zwilling, B. S., et al.
Publicado: (1981)

Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro.
por: Taylor, I. W., et al.
Publicado: (1977)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.
por: Edgar, D. H., et al.
Publicado: (1981)

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
por: Davies, S. L., et al.
Publicado: (1997)

ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
por: Kovacs, C. J., et al.
Publicado: (1979)

ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
por: Kovacs, C. J., et al.
Publicado: (1979)

Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
por: Taylor, I. W., et al.
Publicado: (1977)

The effects of ICRF-154 in combination with other anticancer agents in vitro.
por: Kano, Y., et al.
Publicado: (1992)

Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
por: Perkins, W. E., et al.
Publicado: (1982)

Molecular Characterization of Human Papillomavirus Type 159 (HPV159)
por: Marković, Iva, et al.
Publicado: (2021)

The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
por: de Ridder, Sander, et al.
Publicado: (2020)

Effect of hormones on DNA synthesis in explants from rat and human breast cancers.
por: Hallowes, R. C., et al.
Publicado: (1973)

Moments, monodromy, and perversity (AM-159): a Diophantine perspective (AM-159)
por: Katz, Nicholas M
Publicado: (2005)

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
por: Meikle, I., et al.
Publicado: (1996)

Discussion on P-159 proposal
por: CERN. Geneva. SPS Experiments Committee
Publicado: (1981)

159th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2002)

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
Publicado: (1994)

A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022)

Job burnout in 159 anesthesiology trainees
por: Abut, Yesim Cokay, et al.
Publicado: (2012)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)

Status report of the "dibaryon" experiment S159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1979)

DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation
por: Kawano, Shinji, et al.
Publicado: (2020)

Casein kinase II–dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
por: Nakazawa, Norihiko, et al.
Publicado: (2019)

Different Susceptibilities of Postmitotic Checkpoint‐proficient and ‐deficient Balb/3T3 Cells to ICRF‐193, a Catalytic Inhibitor of DNA Topoisomerase II
por: Nishida, Keiko, et al.
Publicado: (2001)

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study
por: Reimerová, Petra, et al.
Publicado: (2019)

Biology and Function of miR159 in Plants
por: Millar, Anthony A., et al.
Publicado: (2019)

Memorandum: status report on the dibaryon experiment S159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1980)

Status report - experiment S159: dibaryon search
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1979)

Health Tract, No. 159: Civil and Military Death-Rate
Publicado: (1863)

Health Tract, No. 159: Civil and Military Death-Rate
Publicado: (1865)

Proceedings: Mechanism of action studies with IRCF 159: effects on the growth and morphology of BHK-21S cells.
por: Stephens, T. C., et al.
Publicado: (1974)

$\pi^{-}$ p interactions at 1.59 GeV/c
por: Alatti, J, et al.
Publicado: (1963)

W-SBA-15 as an Effective Catalyst for the Epoxidation of 1,5,9-Cyclododecatriene
por: Kujbida, Marcin, et al.
Publicado: (2022)

Abstract 159: Glomus tumour presenting with oncogenic osteomalacia
por: Mathew, Anu
Publicado: (2022)

Memorandum: beam time request for experiment PS 159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1980)

Memorandum: beam time request for experiment PS 159
por: CERN. Geneva. Proton Synchrotron and Synchrocyclotron Committee
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_dagvptej6pn7bk30g396kv5sfr